Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 29.10.2020 | 14:04

Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic

Carl Zeiss Meditec AG / Key word(s): Annual Results
Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic

29-Oct-2020 / 14:04 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic
Jena, October 29, 2020

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of approximately EUR 1,335.5 million in fiscal year 2019/20 (previous year EUR 1,459.3 million) and has thereby exceeded the forecast of approx. EUR 1.3 billion provided on July 15, 2020. This corresponds to a decline of -8.5% vs. the past year. After adjustment for currency effects[1], the decline amounted to -8.7%. In the fourth quarter of 2019/20, revenue reached EUR 367.6 million (Q4 2018/19: EUR 431.7 million), a decline of -14.9%. After adjustment for currency effects, the decline amounted to around -14.5%.

Earnings before interest and taxes (EBIT)[2] amounted to EUR 177.6 million in fiscal year 2019/20 (previous year EUR 264.7 million). EBIT margin (EBIT / revenue) was 13.3% (previous year 18.1%). In the fourth quarter of 2019/20, EBIT amounted to EUR 65.7 million (Q4 2018/19: 80.5 million), EBIT margin was 17.9% (Q4 2018/19: 18.6%).

Earnings per share (EPS)[3] declined to EUR 1.37 (previous year EUR 1.79). In the fourth quarter of 2019/20, EPS was EUR 0.60 (Q4 2018/19: EUR 0.57).

Full results for fiscal year 2019/20 will be provided on Dec 11, 2020.

Carl Zeiss Meditec broadly expects a recovery of its markets in fiscal year 2020/21 and thereby a return to growth in revenue and EBIT. Due to the current trend in COVID-19 infections in Europe and North America, an additional impact from the pandemic cannot be ruled out at the outset of the new fiscal year, though. From today's point of view, the company expects revenue and EBIT for the first months of the new fiscal year 2020/21 to come in below last year's values for the same period.
 

 

Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com

 

[1] Currency-adjusted sales growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.
[2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2018/19, p. 76 for reconciliation).
[3] Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2018/19, p. 76 for reconciliation).


29-Oct-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

ESG-Whitepaper im Fokus

The Corporate ESG Guide: A 360 view on the current landscape and trends

Die ESG-Kriterien (Environmental, Social and Governance) werden auch für Emittenten immer wichtiger, wenn sie für Investoren attraktiv bleiben wollen. In dem Whitepaper “The Corporate ESG Guide: A 360 view on the current landscape and trends” beantworten die Experten von Investor Update grundlegende Fragen von Emittenten. Außerdem kommen Vermögensverwalter, Unternehmensberater Manager und ESG-Ratingagenturen zu wichtigen ESG-Themen zu Wort.

GBC-Fokusbox

"GBC Best of m:access 2020": Neue vielversprechende Auswahl

Unsere letztjährige „GBC Best of m:access“-Auswahl hat sich mit einer Performance von über 50 % überdurchschnittlich stark entwickelt und alle relevanten Indizes hinter sich gelassen. Im Rahmen der vorliegenden aktualisierten Studie präsentieren wir Ihnen eine in Teilen neu zusammengesetzte Selektion, die weiterhin 15 Unternehmen umfasst. Die aktuellen Einschätzungen zu den Einzeltiteln und auch weitere Informationen zur Entwicklung des m:access sind in der vollständigen Studie „GBC Best of m:access 2020“ enthalten.

Aktuelle Research-Studie

EQS Group AG

Original-Research: EQS Group AG (von GSC Research GmbH): Verkaufen

27. November 2020